Since CASP1 is significantly overexpressed in AML and Cytarabine-resistant cells, and is associated with poor prognosis, we inhibited CASP1 with Caspase-1 inhibitor Belnacasan to investigate its role. This evidence concerns the gene CASP1 and acute myeloid leukemia.